Lv1
38 积分 2025-09-15 加入
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation
3天前
已完结
MA15.13 Furmonertinib as Adjuvant Therapy for Completely Resected Stage IA with High-Risk Factors and IB NSCLC Patients with EGFR Mutations
3个月前
已完结
104TiP MRD Evaluation of aumolertinib in EGFR mutation-positive stage IB and stage IA2–3 NSCLC after complete surgical resection: A multicenter, open-label, single-arm study (ASSIST)
3个月前
已完结
MA04.03 Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I A EGFR Mutated NSCLC With High Risk (APPOINT)
3个月前
已完结
Adjuvant icotinib of 12 months versus observation as adjuvant therapy for completely resected EGFR-mutated stage IB non-small-cell lung cancer: 5-year update from CORIN (GASTO1003)
3个月前
已完结
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
3个月前
已完结
Adjuvant Treatments for Surgically Resected Non–Small Cell Lung Cancer Harboring EGFR Mutations
3个月前
已完结
948TiP Efficacy and safety of almonertinib in the adjuvant treatment of resectable stage I non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-sensitizing mutations in solid and/or micropapillary components
4个月前
已完结
Adjuvant icotinib of 12 months versus observation as adjuvant therapy for completely resected EGFR-mutated stage IB non-small-cell lung cancer: 5-year update from CORIN (GASTO1003)
4个月前
已关闭
EP.07.55 Adjuvant Sunvozertinib for Early-Stage NSCLC Patients With EGFR Exon 20 Insertion Mutation: A Case Series
4个月前
已关闭
皖公网安备34019202002308
